Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial-Reference-Cited by-同舟云学术

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Published:2019-10-22 Issue:2 Volume:11 Page:129-141
ISSN:2190-1678
Container-title:Diabetology International
language:en
Short-container-title:Diabetol Int

Author:

Inagaki Nobuya,Yang Wenying,Watada Hirotaka,Ji Linong,Schnaidt Sven,Pfarr Egon,Okamura Tomoo,Johansen Odd Erik,George Jyothis T.,von Eynatten Maximilian,Rosenstock Julio,Perkovic Vlado,Wanner Christoph,Cooper Mark E.,Alexander John H.,Komuro Issei,Nangaku Masaomi

Funder

Boehringer Ingelheim

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13340-019-00412-x.pdf

Reference40 articles.

1. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77(8):1923–32.

2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–40.

3. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64–91.